Last reviewed · How we verify
12-month Edoxaban
12-month Edoxaban, marketed by Takeshi Morimoto, is a well-established anticoagulant with a strong presence in the pharmaceutical market. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue and market share.
At a glance
| Generic name | 12-month Edoxaban |
|---|---|
| Sponsor | Takeshi Morimoto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
- Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) (PHASE3)
- Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1) (PHASE4)
- Pharmacokinetics and Pharmacodynamics of Edoxaban Before and After Bariatric Surgery (PHASE1)
- Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study (PHASE1)
- Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study (PHASE4)
- Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy (PHASE4)
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 12-month Edoxaban CI brief — competitive landscape report
- 12-month Edoxaban updates RSS · CI watch RSS
- Takeshi Morimoto portfolio CI